Truvestments Capital’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,364
| Closed | -$32.2K | – | 896 |
|
|
2023
Q4 | $32.2K | Hold |
1,364
| – | – | 0.01% | 377 |
|
|
2023
Q3 | $20.3K | Hold |
1,364
| – | – | 0.01% | 382 |
|
|
2023
Q2 | $14.9K | Hold |
1,364
| – | – | 0.01% | 414 |
|
|
2023
Q1 | $11.9K | Sell |
1,364
-27
| -2% | -$216 | 0.01% | 424 |
|
|
2022
Q4 | $8.72K | Sell |
1,391
-96
| -6% | -$365 | ﹤0.01% | 472 |
|
|
2022
Q3 | $5K | Hold |
1,487
| – | – | ﹤0.01% | 478 |
|
|
2022
Q2 | $4K | Buy |
+1,487
| New | +$3.55K | ﹤0.01% | 518 |
|
|
2022
Q1 | – | Sell |
-727
| Closed | -$2K | – | 588 |
|
|
2021
Q4 | $2K | Hold |
727
| – | – | ﹤0.01% | 563 |
|
|
2021
Q3 | $3K | Hold |
727
| – | – | ﹤0.01% | 522 |
|
|
2021
Q2 | $3K | Hold |
727
| – | – | ﹤0.01% | 529 |
|
|
2021
Q1 | $3K | Buy |
727
+408
| +128% | +$2.2K | ﹤0.01% | 595 |
|
|
2020
Q4 | $1K | Buy |
+319
| New | +$2.42K | ﹤0.01% | 598 |
|
|
2020
Q3 | – | Sell |
-319
| Closed | -$1K | – | 583 |
|
|
2020
Q2 | $1K | Buy |
+319
| New | +$921 | ﹤0.01% | 561 |
|
|
2019
Q4 | – | Sell |
-558
| Closed | -$3K | – | 639 |
|
|
2019
Q3 | $3K | Sell |
558
-64
| -10% | -$387 | ﹤0.01% | 648 |
|
|
2019
Q2 | $4K | Hold |
622
| – | – | ﹤0.01% | 655 |
|
|
2019
Q1 | $8K | Buy |
+622
| New | +$6.62K | 0.01% | 550 |
|
|
2018
Q3 | $7K | Buy |
+638
| New | +$7.92K | ﹤0.01% | 707 |
|
Other funds holding CBAY
Truvestments Capital's CBAY Position: Q1 2024 in Review
Truvestments Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 1,364 shares — an estimated $32.2K sold.
Truvestments Capital first reported a position in CBAY in Q3 2018 and held it in 17 quarters. The position peaked at $32.2K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Truvestments Capital reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Truvestments Capital sold 1,364 Cymabay Therapeutics shares in Q1 2024, an estimated $32.2K.
- Truvestments Capital first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 17 quarters.
- Truvestments Capital's Cymabay Therapeutics position peaked at $32.2K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Truvestments Capital's 13F filing for Q1 2024, filed 14 May 2024.